0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TPBG

TPBG

Brief Information

Name:Trophoblast glycoprotein
Target Synonym:Trophoblast glycoprotein,5T4 oncotrophoblast glycoprotein,5T4,TPBG,5T4 oncofetal antigen,M6P1,5T4 oncofetal trophoblast glycoprotein,Wnt-Activated Inhibitory Factor 1,WAIF1,5T4AG,5T4-AG
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Part of Bioactivity data

TPG-M52H3-MALS-HPLC
Mouse TPBG, His Tag (Cat. No. ) MALS images

The purity of Mouse TPBG, His Tag (Cat. No. TPG-M52H3) was more than 90% and the molecular weight of this protein is around 53-65 kDa verified by SEC-MALS.

  • Background
    Trophoblast glycoprotein (TPBG), also known as 5T4, is the therapeutic target of several anticancer agents currently in clinical development, largely due to its high expression in tumors and low expression in normal adult tissues.This gene encodes a leucine-rich transmembrane glycoprotein that may be involved in cell adhesion. TPBG is expressed by all types of trophoblasts as early as 9 weeks of development.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

    TPG-H5253-MALS-HPLC
    Human TPBG, Fc Tag (Cat. No. ) MALS images

    The purity of Human TPBG, Fc Tag (Cat. No. TPG-H5253) was more than 90% and the molecular weight of this protein is around 158-192 kDa verified by SEC-MALS.

Synonym Name

TPBG,5T4,M6P1,5T4AG,WAIF1,5T4 oncofetal antigen,Trophoblast glycoprotein,5T4 oncofetal trophoblast glycoprotein

Background

Trophoblast glycoprotein (TPBG), also known as 5T4, is the therapeutic target of several anticancer agents currently in clinical development, largely due to its high expression in tumors and low expression in normal adult tissues.This gene encodes a leucine-rich transmembrane glycoprotein that may be involved in cell adhesion. TPBG is expressed by all types of trophoblasts as early as 9 weeks of development.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Prostate cancer vaccine, inactivated viral (University of Oxford) Clinical University Of Oxford Prostatic Neoplasms Details
OXB-301 OXB-301; SAR-109659 Phase 3 Clinical Oxford Biomedica Carcinoma, Renal Cell; Prostatic Neoplasms Details
SYD-1875 SYD-1875 Phase 1 Clinical Synthon Bv Neoplasms Details
GEN-1044 GEN-1044 Phase 2 Clinical Genmab Esophageal Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Uterine Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
Naptumomab estafenatox TTS-CD3; ABR-217620 Phase 2 Clinical Active Biotech Carcinoma, Renal Cell; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
ASN-004 ASN-004 Phase 1 Clinical Asana Biosciences Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop